$43.57
-0.06 (-0.14%)
NATL News25 articles
Duke Energy Narrows Residential Rate Increase to 11.6% Amid Regulatory Pressure
Duke Energy Carolinas cut its proposed residential rate increase to 11.6% from 18% after opposition from regulators and the attorney general. The new rate requires approval from the North Carolina Utilities Commission and could take effect Jan. 1, 2027.
T1 Energy Stock Dips Ahead of Vote on Share Increase for KORE Power Deal and Plant Financing
T1 Energy stock slid 3.3% to $8.63 before a vote to double authorized shares to 1 billion, fueling dilution fears tied to the KORE Power buy and G2_Austin solar cell plant funding.
Annaly Capital Holds Steady After Dividend Increase, Eyes Fed Meeting
Annaly Capital Management shares trade flat near $22 after a dividend boost to $0.75 per share, yielding ~13.6%. Market focus shifts to the Federal Reserve's upcoming policy decision.
Annaly Capital Stock Steady Near $22 After Dividend Increase, Fed Meeting in Focus
Annaly Capital Management raised its quarterly dividend to $0.75 per share, boosting its annualized yield to about 13.6%. The stock closed near $22 as investors weigh the payout against interest rate risks.
NCR Voyix Surges 10% on Turnaround Optimism
NCR Voyix surged 10.25% to $7.85, far outpacing the market, as investors focus on 2026 cash-flow and earnings targets. The Q2 2026 earnings update is the next key catalyst.
VS Media Skyrockets 317% Pre-Market on Stake Increase in S T Meng
VS Media Holdings (VSME) surged over 300% pre-market after a debt-to-equity swap increased its stake in S T Meng to 41.52%, but the micro-cap still faces going-concern risks.
Tango Therapeutics Soars as Pancreatic Cancer Combo Shows 92% Response Rate
Tango Therapeutics shares rose sharply in premarket trading Monday after reporting a 92% objective response rate for its pancreatic cancer drug combo, with plans to move into Phase 3 testing.
AIM ImmunoTech Surges on Early Pancreatic Cancer Trial Enrollment Completion
AIM ImmunoTech shares surged over 100% after its Phase 2 pancreatic cancer trial reached final enrollment ahead of schedule, with the primary endpoint readout set for December 2026.
Revolution Medicines Stock Gains Pre-Market on Promising Pancreatic Cancer Data
Revolution Medicines shares gained 1.9% premarket after Phase 3 data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months versus 6.7 months for chemotherapy.
Opendoor Technologies Joins Russell 3000 Index, CEO Increases Stake
Opendoor Technologies (OPEN) shares jumped 6% premarket after the company announced its inclusion in the Russell 3000 Index, effective June 26. CEO Kaz Nejatian purchased 100,000 shares, increasing his stake to 83.58 million.
Ondas Stock Climbs Ahead of Crucial Vote on Share Increase
Ondas shares climbed to $10.10 in premarket trading Wednesday ahead of a shareholder vote on raising authorized shares and expanding the stock plan.
Silexion Advances Pancreatic Cancer Trial Amid Cash Concerns
Silexion Therapeutics progresses its SIL204 pancreatic cancer drug into clinical trials, but a shrinking cash position and recent stock decline highlight funding challenges.
PECO Proposes Major Rate Increases for 2027, Seeks $510M for Infrastructure
PECO has requested regulatory approval for significant delivery rate increases that would raise residential electricity bills by 12.5% and suburban gas bills by 11.4% beginning in 2027. The utility seeks $510 million for infrastructure improvements.
Michigan Regulators Approve $276M Consumers Energy Rate Increase
Michigan regulators have granted Consumers Energy a $276.6 million annual rate increase, raising typical residential bills by $6.46 per month starting May 1. The decision funds grid upgrades but drew criticism from the state's attorney general.
Petrobras Shares Drop on Domestic Diesel Price Increase Amid Government Tax Shift
Petrobras shares declined following a diesel price increase for distributors, set against Brazil's removal of federal diesel taxes and new crude export tax. The state oil giant reported a strong Q4 profit but faces policy headwinds.
Bradesco Shareholders Approve Capital Increase, Eye Healthcare Restructuring
Banco Bradesco secured shareholder approval for a R$6.67 billion capital boost through reserve capitalization, leaving its ADR price unchanged. Investors now await a key March 31 vote on consolidating healthcare assets under Odontoprev.
Fortescue Directors Increase Holdings Following Strong Earnings, Dividend Boost
Multiple Fortescue board members acquired shares in late February, following the iron ore miner's announcement of a 23% jump in first-half earnings and an increased interim dividend. The stock gained 2% on Thursday.
Woodside Directors Increase Holdings Amid Leadership Transition
Woodside Energy's board-linked trustee purchased shares for seven non-executive directors, signaling confidence during a CEO search and major project negotiations. The company's Scarborough project is 94% complete.
Defense Stocks Rally on Middle East Tensions, Fueling Budget Increase Bets
UK defense contractors BAE Systems and Babcock International advanced sharply, countering broader market declines, following escalated Middle East hostilities. Investors are pricing in higher global defense budgets, with the White House targeting a $1.5 trillion U.S. outlay by 2027.
Kingsoft Cloud Shares Slide on Increased Related-Party Lease Caps
Kingsoft Cloud Holdings Limited shares declined 5.6% in early trading following a regulatory filing disclosing elevated annual caps for connected property transactions. Investors are monitoring for further disclosures and upcoming U.S. economic data.
Kingsoft Cloud Shares Slide on Increased Related-Party Lease Caps
Kingsoft Cloud Holdings Limited shares declined 5.6% in early trading following a regulatory filing detailing increased annual caps for related-party property and lease agreements. Investors are monitoring upcoming Hong Kong disclosures and U.S. payrolls data.
NovoCure Shares Surge on FDA Approval for Pancreatic Cancer Device
NovoCure's stock jumped over 20% premarket after the FDA cleared its Optune Pax device for treating locally advanced pancreatic cancer, marking the first new treatment for this condition in nearly three decades.
Walmart Shares Dip Ahead of Earnings Despite Analyst Target Increases
Walmart shares declined 1.65% to $129.02 and extended losses after hours as investors await quarterly results. Analysts at Oppenheimer and Mizuho raised price targets citing strong holiday performance.
Coca-Cola Shares Dip Ahead of Earnings Despite Wells Fargo Target Increase
Coca-Cola stock declined 1.2% to $78.08 as consumer staples underperformed a broader market rebound. Wells Fargo raised its price target to $87 ahead of Tuesday's quarterly results.
Infineon Gains on Planned Power Chip Price Increases, AI Demand Outlook
Infineon shares rose 1.5% Friday following reports of planned price hikes for select power products in April. The company cites tight supply and higher costs, with UBS raising its price target to €47.